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From the initial observations of Menkin and the pivotal experiments of Beeson, 
Wood and Atkins (1), the postulated mechanism for fever in a variety of diseases 
was based on  the  ability of various substances,  usually of microbial  origin,  to 
stimulate phagocytes to synthesize and release a heat-labile protein called endog- 
enous pyrogen  (EP). 1 It was later  shown  that  EP  initiated  fever by increasing 
prostaglandin  PGE2 synthesis in or near the anterior hypothalamus (reviewed in 
2), and that antipyresis was the result of reduced cyclooxygenase activity there 
rather  than  in the  EP-producing cells (3, 4).  During the last decade, it became 
increasingly clear that  EP, in addition to its ability to induce fever, possessed a 
great number of biological activities (5).  Following tedious protein purifications, 
homogeneous EP was shown to stimulate T  cells (6-9), increased hepatic acute- 
phase protein  synthesis (10),  activate  neutrophils  (1 1),  stimulate  prostaglandin 
production  in  vitro  (12),  and  in  general,  mediate  many  components  of the 
generalized acute-phase response (5).  Because of its multiple biological activities, 
and  particularly  its ability to activate  iymphocytes, renaming  EP  interleukin  1 
has become accepted (13). 
Attributing many diverse biological properties to a single molecule created a 
dilemma for investigators.  Despite convincing evidence of the homogeneity of 
various preparations  (8,  9,  14,  15), considerable doubt remained  that  a  single 
polypeptide  possessed  such  diverse  activities.  The  controversy  has  now  been 
resolved; two cDNAs coding for IL-1 have been cloned, a neutral form (16) and 
an  acid  form  (17).  Recombinant  IL-ls  of both  forms  have now been  used  to 
study the multiple biological properties attributed to IL-1. Although the two IL- 
l  forms, representing the two charged species at pI 7 and pI 5 (18), share little 
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amino  acid  homology,  each  recombinant  form  can  induce  the  same  broad 
spectrum of responses, including fever (19). 
During  the  early  investigation  into  the  pathogenesis  of  fever,  there  was 
speculation that another leukocyte product, interferon, also caused fever. From 
the first clinical trials using partially purified IFNs, fever had become the major 
side effect of IFN therapy (20).  Current clinical trials using recombinant forms 
have  confirmed  the  observations  that  IFNs,  particularly  IFN-o~,  cause  fever. 
Recently  (21,  22)  it  was  shown  that  IFN-a  produces  fever  not  because  it  is 
contaminated  with  endotoxins  or  induces  IL-1,  but  rather  because  IFN-a  is 
intrinsically pyrogenic by its direct action on the thermoregulatory center (21, 
22).  Thus,  from  a  conceptual  point  of view,  a  second  molecule  exists  with 
endogenous pyrogen activity, rIFN-a meets the criteria for being an endogenous 
pyrogen: it produces a  brisk,  monophasic fever following intravenous injection 
into  rabbits  and  mice,  is  free  of endotoxins, and  increases  the  production  of 
PGE2 from brain tissue in vitro and in vivo. 
We now report that another leukocyte product, tumor necrosis factor (TNF; 
cachectin) (23), is also intrinsically pyrogenic. Recombinant human tumor necro- 
sis factor (rTNF00 produces a brisk, monophasic fever after intravenous injection 
into  rabbits,  and  the  fever  is  not due  to  contaminating endotoxin.  However, 
unlike IFN-a, rTNF0~ also induces IL-1 in vivo and in vitro. These results, along 
with those observed with IFN-a and IL-1, support an expanded hypothesis for 
the pathogenesis of fever involving several endogenous pyrogens. 
Materials and Methods 
Materials.  Human rTNFc~ was expressed in Escherichia  coli and purified to homoge- 
neity (24).  Limulus amebocyte lysate (LAL) (Mallinckrodt, Inc., St.  Louis, MO) testing 
employed an E.  coil standard (Mallinckrodt, Inc.) and detected 10 pg/ml (0.1 endotoxin 
unit). Various lots of rTNFc~ were tested and revealed 200 pg or less of endotoxin per 
milligram of rTNFa. Adding rTNF~ to known quantities of endotoxin did not interfere 
with the LAL assay. Using gas chromatography/mass spectrometry (5840A and 5985B, 
respectively, Hewlett-Packard Co.,  Palo  Alto,  CA),  /3-hydroxymyristic  acid in  rTNFc~ 
preparations was not detected above background levels (sterile  water was <40 pg/mg). 
Adding known amounts of endotoxin to rTNFc~ resulted in complete recovery of the 
calculated amount of ~-hydroxymyristic acid (25). The human rIL-1 used in these studies 
was the pI 7 form (16), provided by Cistron Technology, Inc. (Pine Brook, NJ). rIL-1 was 
expressed in E.  coil and consisted of amino acids  112-269  of the precursor sequence. 
LAL testing used lysate from Associates of Cape Cod (Woods Hole, MA) with a sensitivity 
of 20 pg/ml (0.2  endotoxin unit) using the E.  coli standard EC-5 (Bureau of Biologics, 
Bethesda,  MD). The  rIL-1  contained 40-80  pg  endotoxin per  milligram of protein. 
Adding rlL-1  to known quantities of endotoxin did not interfere with the LAL assay. 
Human  rIFN-y  was  produced  in  E.  coli  and  purified  to  >98%  purity  (26).  IFN-y 
concentrations were determined in a  cytopathic inhibition assay using A549 cells chal- 
lenged with encephalomyocarditis virus, rlFN-y used in these studies has asp act of 1-2 
x  107  U/mg. Ibuprofen formulated for intravenous injection was provided by Upjohn 
Co., Kalamazoo, MI. 
Trypsin Treatment.  rTNFc~ (2 mg) was incubated with TPCK-treated trypsin (Cooper 
Biomedical, Freehold, NJ) at 37°C.  Trypsin (20/~g) was added at 0,  12, 24, and 36 b. 
After 48  h  of incubation, soybean trypsin inhibitor (160  ug; Sigma Chemical Co., St. 
Louis, MO) was added to each sample. Limulus lysate testing of the trypsinized rTNFc~ 
revealed 1 ng/mg endotoxin. 
Pyrogen  Testing.  New  Zealand-derived female rabbits  weighing ~2.5-3.0  kg (Pine DINARELLO  ET  AL.  1435 
Acres,  Burlington,  VT) were  trained  in  restraining devices for  1 wk  before pyrogen 
testing.  Core  temperature  was  measured  using  indwelling  rectal  thermistors  (Yellow 
Springs  Instruments,  Yellow  Springs,  OH)  and  a  Kaye  Digistrip  Model  II  recorder 
(Bedford, MA). Rectal temperatures were measured every minute, as described previously 
(21).  The murine fever studies used C3H/HeJ mice, individually caged in an ambient 
temperature of 33-34°C. Body temperatures were measured with thermosensitive radi- 
otelemetry devices (XM-FH; Minimitter Co., Inc., Sunriver, OR) implanted subcutane- 
ously. After 2 h of stabilization, each mouse was injected with 0.1  ml of either PBS or a 
dilution of rTNF in PBS (six mice per group). Body temperature was measured at 10-min 
intervals  before  and  after  injection  by  determining  the  frequency emitted  by  each 
telemeter. The signal was detected with a Minimitter RA-1000-TH receiver coupled to a 
digital  frequency counter (Heathkit  SM  2420,  Benton Harbor,  MI) and converted to 
temperature using a previously determined calibration index. 
PGE2 Production and Measurements.  Rabbit hypothalami were removed, minced, and 
incubated for 15 min at 37°C.  After washing to remove PG induced by tissue trauma, 
aliquots were incubated for 60 min with various concentrations ofrTNFa or rIL-1 in the 
presence of clinical  grade polymyxin B (25 pg/ml) (Pfizer, Groton, CT) as previously 
described (21, 28). The supernatants were frozen at -70°C and later assayed for PGE2 
using a specific RIA (Seragen, Boston, MA). 
Human Mononuclear Cell Incubations.  Blood was obtained from healthy donors, and 
the  mononuclear cells  (MNC)  were isolated as previously described (29).  Methods for 
stimulating endogenous pyrogen activity for rabbit pyrogen testing using 5-ml volumes of 
MEM (Microbiological Associates,  Walkersville, MD) have been described in detail (29). 
MNCs were also incubated with IFN-'y and rTNFa for 48 h in  1-ml wells with 2.5 ×  106 
cells/ml. For these experiments, MNCs were suspended in MEM (Gibco, Grand Island, 
NY) containing 10% FCS (Hyclone, Logan, UT). Supernatants were diluted and assayed 
for IL-1 activity on thymocytes. 
IL-1 Murine Thymocyte Assay.  Thymocytes from C3H/HeJ mice (The Jackson Labora- 
tory, Bar Harbor, ME) were removed and used to test IL-1 activity in the supernatants of 
human MNC using augmentation of [3H]thymidine incorporation in response to subopti- 
mal concentrations (1  #g/ml) of PHA-P (Burroughs Wellcome, Research Triangle, NC) 
as previously described (9, 30).  Purified human monocyte IL-1  was used as a standard in 
these assays (9). 
Western Blot Analysis.  Methods for western blot analysis  were used as previously de- 
scribed (37).  Blots were developed using goat anti-rabbit  IgG followed by ~25I-labeled 
protein A (Amersham Corp., Arlington Heights, IL). 
Cytotoxicity Assay.  Cytotoxicity of the murine fibroblast L929 line was used to assay 
rTNFc~ activity (31). 
Results 
Pyrogenicity of rTNFa.  Rabbits  were given an intravenous bolus injection of 
freshly thawed rTNFa diluted and mixed with 1.0 ml of 0.15 M NaCI containing 
250 pg/ml of polymyxin B. As shown in Fig.  1A, rTNFa  and rIL-1 at a dose of 
1 pg/kg produce febrile responses characteristic of endogenous pyrogens, with 
monophasic fevers reaching mean peak elevations 48-54 rain after the injections. 
The injection of 0.1  #g/kg of rTNFa  did not induce significant fever (<0.3 °C), 
whereas  0.1  t~g/kg of rIL-1  induced small  but  significant fever (>0.3°C;  data 
not  shown).  The  fevers produced by either rTNFa  or rlL-1  are unlike  those 
produced by endotoxin in which the monophasic fever reaches peak elevation at 
~90  min after the injection (1). In addition, the amount of endotoxin that was 
detected in either the rTNF~ or rIL-1 was clearly below the minimum pyrogenic 
threshold  for endotoxins in  rabbits  (3-5  ng/kg) (1).  As shown  in  Fig.  1 B,  the 
fever induced by rTNFa  is blocked by prior treatment with the cyclooxygenase 1436 
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FIGURE  I.  (A) Mean fevers of rabbits injected with either rTNFa or rlL-l. The recombinant 
materials were thawed, diluted in polymyxin B and injected intravenously. The numbers in 
parentheses indicate the number of rabbits in each group. (B)  Dose-response of rTNFa in 
rabbits, rTNFa was treated as indicated in A.  Ibuprofen was injected intravenously 10  min 
before rTNFa. DINARELLO  ET  AL.  1437 
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FIGURE  2.  Mean  fevers  in  rabbits injected  with rTNFa  (10  ug/kg)  treated  with  various 
conditions, as indicated. The numbers in parentheses represent the number of rabbits in each 
group. 
inhibitor and antipyretic, ibuprofen (32).  Higher doses of rTNFa  (10  ~g/kg) 
induce biphasic  fevers with  the second fever peak  occurring after  3.5  h.  As 
shown in Fig.  2,  heating rTNF~ for 30 rain at 70°C reduced the second fever 
peak without affecting the initial febrile response. However, the pyrogenicity of 
rTNFa was markedly reduced by trypsin treatment. The cytotoxicity assay of 
trypsinized rTNFa revealed that the treatment reduced biological activity of the 
rTNFa  by -80%  and that heat treatment reduced activity by 50%  (data not 
shown). 
Although the concentrations of endotoxin in the rTNFot (see Materials and 
Methods) were below that which would induce fever in rabbits, we employed the 
endotoxin-resistant C3H/HeJ mouse for additional pyrogen testing. As shown in 
Fig.  3,  rTNFa  produces fever in  these  mice at  1  and  10  ug/kg.  Significant 
elevations of body temperature occurred 40 min after intraperitoneal injections. 
Rabbits  injected daily with  endotoxins develop progressive pyrogenic unre- 
sponsiveness (pyrogenic tolerance). In an attempt to induce pyrogenic tolerance 
to  rTNFa,  injections  of rTNFa  (10  #g/kg)  were  given  to  rabbits  on  four 
consecutive days.  In  general,  no  demonstrable decreases in  febrile responses 
were  observed.  Three  representative  individual  rabbit  febrile  responses  are 
shown in Fig. 4. Rabbit 2 did show decreasing fever with successive injections of 
rTNF. However, this rabbit became ill (diarrhea and lethargy) after the second 
injection and died before the fourth injection. During the course of these studies, 
56 rabbits received repeated injections of rTNFa (all intravenous), and 6 rabbits 
(11%) were found dead in their cages. In contrast, no rabbits receiving repeated 
injections of rIL-1 died. 
To determine the cause of the second fever peak, rabbits injected with rTNFa 
were bled during the uprise  of their second fever peak,  and the  heparinized 1438  FEVER,  TUMOR  NECROSIS  FACTOR,  AND  INTERLEUK1N  1 
0,4 
0.2~ 
. 
0 
'=p<  0,05 
rl =5 
PBS  0.2  1 
r  TNF  Ipg/kgl 
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FIGURE 4.  Febrile responses to four daily injections of rTNFa (10 ug/kg) in three rabbits. 
plasma  was pooled and stored for 24  h  at 4°C.  This plasma  was injected  into 
fresh  rabbits,  and  as  shown  in  Fig.  5,  produced  a  monophasic  fever.  The 
pyrogenicity of the circulating plasma was destroyed by heating at 70°C for 30 
rain.  The heat lability of the plasma factor is similar to that  of rlL-1, as shown 
in  Fig.  1 A.  On  the other hand,  rTNFo~,  heated in the same water bath as the 
rlL-1,  retained  its ability to induce  the  first fever peak  (see Fig.  2).  The  data 
from these  experiments  support  the  concept  that  the  second fever peak after 
rTNFa is due to the production of IL-1 in vivo. 
rTNF~ and rlL-1 Induce Hypothalamic  PGE2 In  Vitro.  The rapid rise in body 
temperature  that  characterizes  the  febrile response  to either  rTNFa  or rlL-1 
suggests a direct hypothalamic stimulation,  most likely mediated,  in part,  by an 
increase  in  PGE2  synthesis.  A  single  intravenous  injection  of ibuprofen  (10 
mg/kg) given immediately before rTNFa  blocked the febrile response, as pre- DINARELLO  ET  AL.  1439 
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FIGURE  6.  Mean  percent increase of PGE2 as measured  in supernantants  of stimulated  rabbit 
hypothalamic minces.  Unstimulated ceils produce 30-60 pg/mg of tissue. 
viously shown for IL-1  (32).  Rabbit hypothalamic minces were incubated with 
rTNFa or rIL-1 for 60 min, and the level of PGE2 was assayed in the supernatant 
media. As reported previously (12, 21, 28), one onehundredth of the amount of 
IL-1  necessary to produce  0.6°C  fever in  rabbits  approximately doubled the 
PGE2 detected in the supernatant of hypothalamic minces after 60 min. As shown 
in  Fig.  6,  the  specific activities of rTNFa and rIL-1  were similar in terms of 
PGE2 production in three separate experiments. 
Production  of IL-I  In  Vitro from  Human  MNC  Incubated  with  rTNFa.  To 
elucidate the probable mechanism by which intravenous injection of rTNFa in 
rabbits  induces the  production  of a  circulating endogenous pyrogen (IL-1  or 1440  FEVER,  TUMOR  NECROSIS FACTOR,  AND  INTERLEUKIN  1 
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F~GURE 7.  Mean  fevers  in  rabbits  injected  with  supernatants derived from human MNC 
stimulated  with rTNFa (50 ng/ml).  Supernatants  from the MNC of two human subjects were 
pooled;  half was heated  (70°C  for  30  rain)  before  injection.  Rabbits  were  injected  with 
supernatants  derived  from  10  n monocytes/kg.  The  numbers  in  parentheses  indicate  the 
number of rabbits used to assay the supernatants. 
TABLE  I 
Neutralization of Pyrogenic Activity in MNC Supernatants by 
Anti-IL-1 
MNC supernatants*  plus:  Mean temperature peak  (o c)O 
Normal rabbit serum*  0.64 +_ 0.08 
Anti-human IL-1  *  0.17 + 0.03 
*  24-h MNC supernatants  were generated in 25-ml flasks containing 5 × 
106 MNC/ml (5  ml/flask)  in the presence  of 100 ng/ml rTNFa.  For 
these experiments,  MNC were isolated from two human subjects. Rab- 
bits were injected with the supernatant derived from 106 monocytes/kg. 
* Anti-IL-1  (15) or normal rabbit serum was mixed at  1% (vol/vol) with 
the MNC supernatants,  incubated overnight at  4°C and centrifuged 
(10,000 g) for 2 min. 
Number of rabbits used to assay supernatants. 
TNF),  human  MNC  were  stimulated  in  vitro  with  various  concentrations  of 
rTNFa,  and the supernatant media were assayed for endogenous pyrogen activity 
in  rabbits.  As  shown  in  Fig.  7,  the  supernatant  medium  from  human  MNC 
incubated for 24 h  with rTNFa  induced a  monophasic fever when injected into 
rabbits.  The  amount  of rTNF~  added  to  the  MNC  (50  ng/ml)  was below  the 
rabbit  pyrogen  threshold  (see  Fig.  1B).  After the  incubations,  the  supernatant 
media were tested for TNF~r activity using an ELISA, and there was no increased 
TNFa  in the supernatant  over the amount that was added exogenously (data not 
shown).  The  pyrogenic activity in  these  supernatants  was destroyed by heating 
at 70°C for 30 min, suggesting that this was likely due to IL-1 and not monocyte- 
derived  TNF/cacbectin.  As shown  in  Table  I,  the  monophasic  fever-inducing 
activity in  the  stimulated  MNC  supernatants  was  IL-1, since  it  was  neutralized 
by anti-human  monocyte IL-1. This  antibody did  not recognize human  rTNF 
or naturally-derived  cachectin,  as determined  by western  blot analysis  (Fig.  8). 
Anti-IL-1 had no effect on rTNF~  in the cytotoxicity assay (data not shown). 
The  dose  response  of  rTNFo~  induction  of  IL-1  is  shown  in  Fig.  9.  At DINARELLO  ET  AL.  1441 
FIGURE 8.  Western blot analysis of anti-IL-1. Lanes 1-3 each contain 1 #g purified natural 
cachectin (37). Lane 1 was developed with anticachectin (1:200); lane 2 with anti-IL-1 (1:100) 
(15); and lane 3 with anti-human rTNFa (1:200). Lanes 4-6 each contain 10 pg human riL- 
l.  Lane 4  was developed with anticachectin; lane 5  with anti-human ]L-l; and lane 6  with 
anti-rTNFa. 
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FIGURE 9.  Mean peak fever 4- SEM  in rabbits injected with materials indicated under the 
abscissa. All MNC incubations were in the presence of 12.5 pg/ml polymyxin B. The numbers 
in parentheses indicate the number of rabbits used to assay the pyrogenic activity in the MNC 
supernatants. 
concentrations of 10-500 ng/ml, rTNF induced IL-1 (as measured by peak fever 
in rabbits).  The amount  of rTNFa  that  induced  IL-1  was optimal between 50 
and 100 ng/ml, whereas concentrations of 500 ng/ml induced less IL-1 (although 
not significantly  different  from  100  ng/ml,  p  >  0.05).  Heating rTNFa  for 30 
min at  70°C destroyed its ability to induce  IL-1  in vitro; this finding confirms 
the observation that heat-treated rTNF~ does not induce a second fever peak in 
rabbits (see Fig. 2). 
As expected, supernatants  of human  MNC stimulated with rTNFo~ contained 
IL-1, as measured by augmentation  of T  cell proliferation  in response to PHA 
(Table  II).  The  IL-l-inducing  property  of rTNFa  was  sensitive  to  heat  and 1442  FEVER,  TUMOR  NECROSIS  FACTOR,  AND  INTERLEUK1N  1 
TABLE  II 
Production of lL-1 by Human MNC In Vitro 
Additions to MNC 
[SH]TdR incorporation (cpm)* 
Donor 1  Donor 2  Donor 3  Donor 4 
None (MNC control)  6,763  4,711  5,096  4,793 
rTNFa (ng/ml) 
1  35,049  10,212  13,542  ND 
10  48,924  20,118  8,366  ND 
100  24.864  9,426  7,254  10,471 
100; trypsinized  ND  ND  ND  4,470 
Trypsin only  ND  ND  ND  6,086 
Endotoxin (10 ng/ml)  125,864  33,824  64,357  ND 
* Mean counts per minute of [3H]TdR incorporation.  SD of triplicate wells were 5- 
10% of the mean. MNC supernatants were diluted 1:20 and  1:200 in the thymocyte 
assay.  Only 1:20 data are shown. 
trypsinization. However, the amount of IL-1 detected in the T  cell assay was less 
than  that assayed in  endotoxin-stimulated MNC  supernatants.  This may have 
been due to interference of TNFct in the IL-1 assay, although incubating rlL-1 
with rTNF~ in the thymocyte assay resulted in only slight inhibition of the IL-1 
activity (data not shown). It is also possible that rTNFc~ stimulated the production 
of inhibitory substances from the mononuclear cells. Although detection of these 
IL-l-inhibiting substances in the rabbit pyrogen assay is unlikely, several inves- 
tigators (33) have shown that stimulated monocytes release substances that inhibit 
T  cell proliferation in this assay. 
Production of IL-1 from human MNC by rTNF~ was enhanced by coincuba- 
tion  with  rlFN-7.  As  depicted  in  Fig.  10,  rlFN-7  (1  ng/ml)  enhanced  IL-1 
production by rTNFo~ at 0.25 ng/ml. 
rTNF~ has no intrinsic proliferation-enhancing activity except at high concen- 
trations (500 ng/ml; p  <  0.05) (Fig.  11). This activity may reflect the induction 
of IL-1 from contaminating murine thymic epithelial cells or macrophages, since 
it was neutralized with anti-mouse IL-1. In situ production of IL-1  during the 
T  cell assay has been observed with other substances, such as the polypeptide 
toxin elaborated by certain strains of toxic shock syndrome-associated Staphylo- 
coccus aureus (34). 
Discussion 
These studies show that rTNFa causes fever because it is intrinsically pyrogenic 
and is capable of increasing hypothalamic PGE2 synthesis. Following an intrave- 
nous injection of 1 #g/kg,  rabbits develop monophasic fevers that reach peak 
elevations after 45-55  rain and then return to baseline levels. The only other 
well-defined substance of leukocyte origin that produces this rapid increase in 
core  temperature  is  IL-1.  Because  it  is  a  product  of stimulated  leukocytes, 
TNF/cachectin must  now be  considered an  endogenous pyrogen.  In  Phase  I 
clinical trials, rTNFt~ injected into humans is pyrogenic (S. Sherwin and S. Saks, 
unpublished observations). Mice passively immunized with anticachectin antibod- 
ies survive a lethal dose of endotoxin but still develop fever (35).  In these mice DINARELLO  ET  AL.  1443 
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it is likely that both cachectin and IL-1 are produced, but IL-1 is not neutralized 
by the anticachectin antibody. Thus, it is IL-1  that probably mediates the fever 
in  these  passively  immunized  mice.  It  appears  that  rTNF~  and  rlL-1  have 
approximately the same specific activities in terms of their ability to induce rapid- 
onset fevers after intravenous  injection  in  mice and  rabbits.  At present,  there 
are  no  studies  of rlL-1  injected  into  human  subjects,  and  the  sensitivity  of 
humans  to IL-1  remains to be studied.  Although  there is another  endogenous 
pyrogen,  IFN-o~ (21,  22),  the  amount  of IFN-~  required  to produce  fever in 
rabbits or mice is  100-fold greater than  rlL-1  or rTNF~.  However, IFNs have 
known species specificities which may explain this dose-relationship in nonhuman 
species. 
From  clinical  and  laboratory  data,  three  leukocyte  products  can  now  be 
identified as being endogenous pyrogens, IL-1, IFN-~ and TNF/cachectin. What 
remains to be established is whether any or one or all three of these substances 
mediates the febrile response to a particular disease.  In patients with infectious 
diseases  in  which  endotoxin  plays  a  pathogenic  role,  it  is  likely  that  all  are 
produced.  Extensive laboratory evidence has established that  endotoxin  stimu- 
lates TNF/cachectin  production  (36,  37),  IL-1  (13),  and  IFN production  (38, 
30). However, it may be that in some viral diseases, i.e., cytomegalic disease and 
hepatitis B, IFN predominates as the primary endogenous pyrogen, since many 
components  of  the  acute-phase  response  are  not  induced  by  IFN  and  are 
frequently absent in various viral diseases. Likewise, TNF/cachectin  may be the 
mediator of fever in certain parasitic diseases. Considerable clinical and labora- 
tory  investigation  remain  before  the  role  of each  or  combinations  of these 
endogenous pyrogens can be established in a comprehensive explanation for the 
pathogenesis of fever. 
The recently reported amino acid sequences of human TNF-~ (94), cachectin 
(23) and  IL-1  (16, 40) indicate no obvious sequence homologies. Two forms of 
I L-1 have been identified (16, 17), which correspond to the two isoelectric points, 
pI 7 and 5. These two forms were originally described as endogenous pyrogens 
in  1974 (18),  but their  physical  relationship  at that  time was not clear.  At the 
amino acid level, these two forms share little homology; however, at the carboxyl 
end of each form,  38% absolute and  78%  conserved sequence homology exist 
(41),  and  it seems likely that  the active site for the biological properties which 
the  two  IL-1  forms  share  resides  in  these  sequences.  Nevertheless,  when  the 
shared carboxyl segments are matched with TNF~ or iymphotoxin (TNFI3), no 
striking  sequence homology can be observed.  Despite their  independent  struc- 
ture,  TNF/cachectin  and  IL-1  both  produce  fever,  stimulate  neutrophils  (11, 
42), induce synovial cell collagenase production (43), decrease lipoprotein lipase 
(37, 44), and are cytotoxic for tumor cells (45, 46). 
Using rTNFo~ in these studies, as has been shown (37) using purified natural 
cachectin, TNF/cachectin  has no IL-1 activity on T  cells. This may explain the 
findings  of Damais  et al.  (47),  who reported  that  muramyl  dipeptide  polyala- 
nine/lysine stimulated macrophages to release a pyrogenic substance that  is not 
active on  lymphocytes.  Induction  of TNF/cachectin  would explain  the activity 
responsible for the fever-producing property of these supernatants. 
At higher  doses, rTNFc~  induces a  biphasic  fever.  Using passive transfer  of D1NARELLO  ET  AL.  1445 
plasma taken  during  the rise of the second fever peak, a  circulating  substance 
produced a  monophasic fever when injected into new rabbits.  This circulating 
pyrogenic substance is probably not residual rTNFa, since the pharmacokinetics 
of rTNF and  natural  cachectin  indicate  that  >95%  of the injected  material  is 
cleared  from  the  circulation  in  3  h  (48).  The  experiments  presented  in  the 
present  study suggest  that  the  second  fever peak  represents  IL-1  induced  by 
rTNFa in vivo. To support this observation, rTNFa was shown to induce IL-1 
production from human  MNC in vitro.  Although the rabbit pyrogen assay was 
used  to  test  the  IL-1  content  of the  stimulated  MNC  supernatants,  it  can  no 
longer be assumed that brisk monophasic fevers in rabbits is a valid assay for the 
presence of IL-1. As a result of these studies, it is now clear that either rTNFa 
or rIL-1  induce indistinguishable  fevers within 60 rain of intravenous injection. 
Thus, the endogenous pyrogen assay in rabbits requires conditions for specificity. 
At present,  these seem to be (a) the ability of heating  at  70°C for  30  rain  to 
destroy the fever-inducing property of IL-1  but not rTNFa,  and (b) the use of 
an anti-human  IL-1, which neutralizes  IL-l's pyrogenic property but does not 
recognize  TNF/cachectin.  Using these  two conditions,  it  seems clear  that  the 
pyrogenic moiety in  rTNFa-stimulated  MNC supernatants  is  indeed  IL-1  and 
not more TNF. The use of the T  cell assay was also important in demonstrating 
that rTNFa induces IL-1, since TNF/cachectin is not active on T  cells. 
The  biphasic  fever curve  seen after  administration  of rTNFa  suggests that 
rTNFa has two separate effects: the induction of PGE2 and the induction of IL- 
l. The initial  fever peak (PGEz-mediated) has a  much lower threshold  (<1  /~g/ 
kg) than  the secondary fever peak (IL-l-mediated) in which the dose of rTNFa 
must be between 5 and  10 #g/kg in order to evoke the delayed fever (Fig.  1 B). 
In addition, the primary response is not abolished by prior heating of rTNFa at 
70°C for 30 min,  whereas the secondary response is completely eliminated  by 
this treatment. However, based on the cytotoxicity assay, the heat-treated rTNFa 
still  retains 20% of its original activity. The loss of the secondary fever response 
probably reflects this  decrease in potency. Currently,  we have no evidence for 
the presence of two distinct receptors mediating  these two effects for rTNFa, 
but is seems unlikely that a single receptor would have two different thresholds, 
each mediating a separate response such as the production of PGE2 and IL-1. 
Previous  work  (49)  has  shown  that  colony-stimulating  factors  induce  IL-1 
production.  In addition, there are partially characterized lymphokines, secreted 
in  response  to  mitogen  or antigen,  which  induce  monocytes to produce  IL-1 
(50-52). The present studies raise the question of whether one of these lympho- 
kines  is  lymphotoxin  (TNF3),  since  this  molecule  is  closely  related  to 
TNF/cachectin (24). 
These studies shed light on the long-unexplained finding (53-55) that during 
the second fever peak in rabbits given intravenous injections of influenza virus, 
the plasma contained a substance which, when injected into new rabbits, induced 
another biphasic fever. It had been established that the pyrogenic moiety circu- 
lating during  the second fever peak was not due to remaining  virus but rather 
to  a  host  product.  It  was also  shown  that  fever-inducing  factor(s) circulating 
during  the plasma-induced  second fever peak contained characteristic  endoge- 
nous pyrogen (54), and it now seems certain that this pyrogen was IL-1. However, 1446  FEVER,  TUMOR  NECROSIS  FACTOR,  AND  INTERLEUKIN  1 
using large amounts of purified rabbit IL-1, only monophasic fevers have been 
observed (P.  Murphy,  personal  communication).  Thus,  the  concept  that  IL-1 
induces more IL-1  in vivo has been difficult to substantiate even using in vitro 
production  methods (55).  Considering  the data of the present report,  it seems 
possible that  the circulating  factor detected by passive transfer of plasma from 
febrile rabbits may have been to due to TNF/cachectin rather than IL-1. 
Summary 
Recombinant  human  tumor  necrosis  factor  (rTNFa)  injected  intravenously 
into rabbits produces a rapid-onset, monophasic fever indistinguishable from the 
fever produced by rIL-1. On a weight basis (1 t~g/kg) rTNFe and rIL-1 produce 
the  same  amount  of fever  and  induce  comparable  levels  of  PGE~  in  rabbit 
hypothalamic cells in vitro; like IL-1, TNF fever is blocked by drugs that inhibit 
cyclooxygenase. At  higher  doses (10 ug/kg)  rTNFa  produces biphasic  fevers. 
The first fever reaches peak elevation 45-55 min after bolus injection and likely 
represents a  direct action  on the  thermoregulatory  center.  During  the second 
fever peak (3 h  later), a  circulating endogenous pyrogen can be shown present 
using passive transfer of plasma into fresh rabbits.  This likely represents the in 
vivo induction of IL-1. In vitro, rTNFa induces the release of IL-1 activity from 
human  mononuclear cells with maximal  production observed at 50-100 ng/ml 
of rTNFa.  In  addition,  rTNFo~ and  rIFN-3,  have a  synergistic  effect on  IL-1 
production. The biological activity of rTNF~ could be distinguished from IL-1 
in three ways: (a) the monophasic pyrogenic activity of rIL-1  was destroyed at 
70°C,  whereas rTNFo  remained  active; (b) anti-IL-1  neutralized  IL-1  but did 
recognize rTNFa or natural cachectin nor neutralize its cytotoxic effect; and (c) 
unlike IL-1, rTNFa was not active in the mitogen-stimulated T cell proliferation 
assay.  The  possibility that  endotoxin  was responsible for rTNFa  fever and/or 
the induction of IL-1 was ruled-out in several studies: (a) rTNFa produced fever 
in  the  endotoxin-resistant  C3H/HeJ  mice;  (b)  the  IL-l-inducing  property  of 
rTNFa was destroyed either by heat (70 ° C) or trypsinization, and was unaffected 
by polymyxin B;  (c) pyrogenic  tolerance  to daily  injections of rTNFe  did not 
occur; (d)  levels of endotoxin,  as determined  in  the Limulus amebocyte lysate, 
were below the minimum rabbit pyrogen dose; and (e) these levels of endotoxin 
were  confirmed  by  gas  chromatography/mass  spectrometry  analysis  for  the 
presence  of t3-hydroxymyristic acid.  Although  rTNFo~  is  not  active  in  T  cell 
proliferation assays, it may mimic IL-1 in a T  cell assay, since high concentrations 
of rTNF~  induced  IL-1  from epithelial  or macrophagic  cells in the thymocyte 
preparations.  These  studies show that  TNF (cachectin) is another  endogenous 
pyrogen  which,  like  IL-1  and  IFN-~,  directly  stimulate  hypothalamic  PGE~ 
synthesis. In addition, rTNFe is an endogenous inducer of IL-1. Together, these 
results support the concept that the febrile response to infection is a fundamental 
event  in  host  defense  and  the  induction  of fever by endogenously  produced 
molecules is not imparted to a single substance. 
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